These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22899372)

  • 1. Statistical methods for assessing interchangeability of biosimilars.
    Chow SC; Yang LY; Starr A; Chiu ST
    Stat Med; 2013 Feb; 32(3):442-8. PubMed ID: 22899372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics.
    Hsieh TC; Chow SC; Yang LY; Chi E
    Stat Med; 2013 Feb; 32(3):406-14. PubMed ID: 22899403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific considerations for assessing biosimilar products.
    Chow SC; Wang J; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):370-81. PubMed ID: 22933240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the interchangeability of biologic drug products.
    Endrenyi L; Chang C; Chow SC; Tothfalusi L
    Stat Med; 2013 Feb; 32(3):434-41. PubMed ID: 22911936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adapted F-test for homogeneity of variability in follow-on biological products.
    Yang J; Zhang N; Chow SC; Chi E
    Stat Med; 2013 Feb; 32(3):415-23. PubMed ID: 22933180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics.
    Zhang N; Yang J; Chow SC; Chi E
    J Biopharm Stat; 2014; 24(6):1239-53. PubMed ID: 25036940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation and approximation approaches for biosimilar index based on reproducibility probability.
    Yang LY; Lai CH
    J Biopharm Stat; 2014; 24(6):1298-311. PubMed ID: 25033191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of variability on the choice of biosimilarity limits in assessing follow-on biologics.
    Zhang N; Yang J; Chow SC; Endrenyi L; Chi E
    Stat Med; 2013 Feb; 32(3):424-33. PubMed ID: 22933127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins.
    Li Y; Liu Q; Wood P; Johri A
    Stat Med; 2013 Feb; 32(3):393-405. PubMed ID: 22991275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of the parallel line assay to assessment of biosimilar products based on binary endpoints.
    Lin JR; Chow SC; Chang CH; Lin YC; Liu JP
    Stat Med; 2013 Feb; 32(3):449-61. PubMed ID: 22911920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific factors and current issues in biosimilar studies.
    Chow SC; Endrenyi L; Lachenbruch PA; Mentré F
    J Biopharm Stat; 2014; 24(6):1138-53. PubMed ID: 25098559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical test for evaluation of biosimilarity in variability of follow-on biologics.
    Hsieh TC; Chow SC; Liu JP; Hsiao CF; Chi E
    J Biopharm Stat; 2010 Jan; 20(1):75-89. PubMed ID: 20077250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparability and biosimilarity: considerations for the healthcare provider.
    Lee JF; Litten JB; Grampp G
    Curr Med Res Opin; 2012 Jun; 28(6):1053-8. PubMed ID: 22519391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars - terms of use.
    Declerck P; Mellstedt H; Danese S
    Curr Med Res Opin; 2015 Dec; 31(12):2325-30. PubMed ID: 26397731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical assessment of biosimilarity based on relative distance between follow-on biologics.
    Kang SH; Chow SC
    Stat Med; 2013 Feb; 32(3):382-92. PubMed ID: 22941672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.
    Dowlat HA; Kuhlmann MK; Khatami H; Ampudia-Blasco FJ
    Diabetes Obes Metab; 2016 Aug; 18(8):737-46. PubMed ID: 27097592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.